Accelerant Holdings

Accelerant Holdings’ $4 billion-plus take-private by Thoma Bravo puts the spotlight on a business where Exchange Services and MGA Operations generated about 98% of second-quarter segment adjusted EBITDA, underscoring the specialty insurance platform’s increasingly fee-driven earnings model. Representative image.

General business news

Accelerant gets 98% of Q2 segment EBITDA from fee businesses. That helps explain Thoma Bravo’s $4bn bet

Accelerant Holdings generated $104.3 million of Q2 adjusted EBITDA from Exchange Services and MGA Operations, versus only $1.9 million from underwriting. The numbers reveal why a software-focused buyer may see more than an insurance company.

bySrinath

August 16, 2026

Accelerant Holdings’ $4 billion-plus take-private deal with Thoma Bravo values the specialty insurance risk exchange operator at $20.25 per share, a 49% premium to its August 12 closing price, ending its public-market run just over a year after its New York Stock Exchange debut. Representative image.

General business news

One year after IPO: Accelerant (NYSE: ARX) agrees to $4bn Thoma Bravo take-private

Thoma Bravo's $20.25 per share offer values Accelerant Holdings at over $4bn, ending the specialty insurance platform's year on the NYSE at a 49% premium.

bySrinath

August 15, 2026

Technology Industry News

Can Accelerant’s $724m ARX IPO make its risk exchange a benchmark for insurtech growth in 2025?

Accelerant’s $724M ARX IPO shows insurtech’s comeback. Learn how its risk exchange and growth plans could reshape specialty insurance.

byPallavi Madhiraju

July 24, 2025

The Latest

PMV’s $79.4m cash pile now hinges on rezatapopt’s 2027 ovarian cancer FDA bid

NFI Group’s backlog shrank 10.6% as earnings surged. How can both be true?

Frontera Energy (TSX: FEC) Q2 puts early-2027 LNG launch in focus

Shell plc (LSE: SHEL) blocked from Wild Coast exploration as South Africa faces investment test

Accelerant gets 98% of Q2 segment EBITDA from fee businesses. That helps explain Thoma Bravo’s $4bn bet

One year after IPO: Accelerant (NYSE: ARX) agrees to $4bn Thoma Bravo take-private

Can Accelerant’s $724m ARX IPO make its risk exchange a benchmark for insurtech growth in 2025?

PMV’s $79.4m cash pile now hinges on rezatapopt’s 2027 ovarian cancer FDA bid

NFI Group’s backlog shrank 10.6% as earnings surged. How can both be true?

Frontera Energy (TSX: FEC) Q2 puts early-2027 LNG launch in focus

Shell plc (LSE: SHEL) blocked from Wild Coast exploration as South Africa faces investment test

Polish pilgrim bus crash kills 12 in Hungary as driver fatigue becomes focus of M3 investigation

New Alzheimer’s imaging approval could help unlock Lantheus’ neurology merger payouts

Standard Bank (JSE: SBK) profit rises 10% despite margin pressure as Africa growth bet enters new phase

Grasim Q1 adjusted profit jumps 49% as Birla Opus and Birla Pivot scale, but net debt rises